How Zai Lab Navigated China’s Biotech Regulatory Landscape: Case Study

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) stands as one of the most instructive case studies for how a China-based, globally oriented biopharmaceutical company can successfully navigate China’s complex and rapidly evolving drug regulatory environment. Founded in 2014 by Dr. Samantha Du, a seasoned pharmaceutical executive with deep experience at Pfizer and Novartis, Zai Lab pursued a distinctive “China + Global” strategy that leveraged regulatory pathways unique to China — including the Center for Drug Evaluation (CDE) priority review mechanisms, the accelerated approval pathways introduced under the 2017–2020 drug regulatory reforms, and the innovative simultaneous IND/NDA filing model across China and the United States.

This case study examines the specific regulatory strategies Zai Lab employed, the obstacles it faced, and the lessons foreign and China-based biotech firms can draw from its trajectory.

Company Background and Regulatory Context

When Zai Lab was founded in 2014, China’s drug regulatory environment was undergoing a fundamental transformation. The previous decade had been characterized by multi-year approval backlogs, an insistence on domestic clinical trial data for foreign-developed drugs, and limited incentives for innovation. The State Council’s 2015 “Opinions on the Reform of the Review and Approval System for Drugs and Medical Devices” initiated a wave of reforms that accelerated under the newly restructured National Medical Products Administration (NMPA, formerly CFDA).

Zai Lab’s founding strategy was built on three regulatory pillars:

1. In-licensing global innovation: Bringing late-stage or approved therapies from global biopharma companies into China, where Zai would conduct bridging studies and navigate local regulatory approval
2. Parallel global development: Filing Investigational New Drug (IND) applications simultaneously in China and the United States to minimize delays in global clinical trial programs
3. Leveraging reform-era regulatory incentives: Utilizing priority review, breakthrough therapy designation, and conditional approval pathways introduced during the 2017–2020 period

This strategy required deep mastery of an evolving regulatory system — and Zai Lab’s success offers a playbook for navigating the NMPA’s shifting requirements.

Key Regulatory Strategy 1: The Priority Review and Accelerated Approval Pathway

Zai Lab’s first major regulatory achievement was the NMPA approval of Zejula (niraparib) — a poly ADP-ribose polymerase (PARP) inhibitor for ovarian cancer maintenance therapy — in December 2019. Zai had acquired the China rights from Tesaro (later acquired by GSK) in 2016, when Zejula was still in global Phase III trials.

The regulatory pathway Zai Lab pursued was groundbreaking for several reasons:

• Priority review designation: Zai submitted Zejula to the CDE under the newly established priority review mechanism (introduced in 2017 under NMPA Announcement No. 102 of 2017). The CDE granted priority review based on Zejula’s status as a meaningful therapeutic advance over existing treatment options for Chinese ovarian cancer patients
• Bridging study strategy: Rather than conducting a full China-specific Phase III trial, Zai successfully argued that the global Phase III ENGOT-OV26/NOVA trial data (which included a limited number of Chinese patients) was sufficient for approval when supplemented by a local bridging study. This reduced the clinical development timeline by an estimated 2–3 years compared to a full China-exclusive development program
• Conditional approval: Zejula was approved under NMPA’s conditional approval pathway, requiring post-marketing confirmatory studies and ongoing safety monitoring. This allowed Zai to bring the drug to market 18–24 months earlier than traditional approval timelines would have permitted

The result was a regulatory review time of approximately 12 months from filing to NMPA approval — significantly faster than the average NMPA review that at the time still averaged 18–24 months for new drug applications. Zejula became the first PARP inhibitor approved in China for the maintenance treatment of platinum-sensitive recurrent ovarian cancer.

Key Regulatory Strategy 2: Simultaneous IND Filing and Global Trial Integration

A defining feature of Zai Lab’s regulatory approach was its systematic use of simultaneous IND filings in China and the United States. This strategy, made possible by the NMPA’s 2018 acceptance of foreign clinical trial data (under the 2018 “Announcement on Adjusting the Requirements for Drug Clinical Trial Review and Approval”), allowed Zai to:

• File IND applications for multiple drug candidates in China within weeks of their US FDA submissions
• Integrate Chinese clinical trial sites into global Phase II/III protocols — ensuring that Chinese patient data was included in the global registration dataset
• Reduce clinical development timelines by 2–4 years compared to the traditional sequential approach (US first, China later)

The most prominent example was Qinlock (ripretinib), a KIT/PDGFRA inhibitor for gastrointestinal stromal tumors (GIST). Zai Lab in-licensed Qinlock from Deciphera Pharmaceuticals and simultaneously initiated the Chinese portion of the global Phase III INVICTUS trial. When the US FDA approved Qinlock in May 2020, Zai was already well advanced with the Chinese clinical program. The NMPA approved Qinlock in March 2021 — less than 10 months after the US approval — making it one of the fastest China-US approval gaps for an innovative oncology drug at that time.

This strategy required careful coordination with both the FDA and the CDE to ensure that the Chinese trial sites followed ICH E6 Good Clinical Practice (GCP) standards acceptable to both regulators. Zai established a dedicated regulatory affairs team that maintained continuous dialogue with CDE reviewers during the clinical trial phase — a practice that is now widely adopted but was innovative at the time.

Key Regulatory Strategy 3: Navigating the CDE’s Breakthrough Therapy Designation

Zai Lab was also an early adopter of China’s Breakthrough Therapy Designation (BTD) pathway, introduced by the NMPA in 2020 under the “Procedures for Breakthrough Therapy Designation of Drugs.” The BTD mechanism allows drugs that demonstrate substantial improvement over existing therapies for serious conditions to receive enhanced regulatory guidance, rolling review, and priority examination.

Zai’s portfolio included several BTD recipients:

The BTD strategy was resource-intensive — each application required robust clinical data packages demonstrating the claimed improvement over standard of care — but the payoff in reduced review timelines was substantial. Zai’s regulatory affairs team calculated that BTD designations reduced overall time-to-market by an average of 6–8 months across the portfolio.

Obstacles and Challenges

Zai Lab’s regulatory journey was not without significant obstacles. Understanding these challenges is as instructive as studying the successes:

Challenge 1: Changing CDE Expectations for Bridging Studies

Between 2019 and 2022, the CDE’s expectations for bridging study design evolved significantly. Early approvals (like Zejula) were granted with relatively limited local data, but by 2022, the CDE began demanding more robust China-specific safety and efficacy data — including larger sample sizes, longer follow-up periods, and head-to-head comparisons with local standard of care. This forced Zai to adjust its clinical development plans for later-stage pipeline assets, increasing trial enrollments from the original projections.

Lesson: The CDE’s standards are not static. Companies must maintain continuous engagement with CDE reviewers and be prepared to scale their China clinical programs as regulatory expectations evolve.

Challenge 2: Price Negotiation and Volume-Based Procurement (VBP)

While regulatory approval was Zai Lab’s first hurdle, pricing under China’s National Reimbursement Drug List (NRDL) negotiation process proved equally challenging. Zai’s innovative oncology drugs faced steep price reductions during NRDL negotiations — ranging from 40% to 70% off the initial market price. This created tension between the original in-licensing economics (based on global pricing) and China’s affordability requirements.

Zai addressed this by developing rigorous health economics and outcomes research (HEOR) dossiers for each product, demonstrating cost-effectiveness at the negotiated price. The company also structured its in-licensing agreements with global partners to include China-specific pricing tiers, reducing the royalty burden when NRDL prices were lower.

Challenge 3: Onshoring Manufacturing Compliance

The NMPA has increasingly emphasized localized manufacturing, particularly for biologics and complex small molecules. Zai’s early products were manufactured by global partners and imported into China. But under the 2019 “Administrative Measures for Drug Registration” and subsequent guidance, the NMPA signaled a preference for local production. Zai responded by building its own GMP-compliant manufacturing facility in Suzhou (completed in 2021) and establishing an in-house quality management system that meets both NMPA GMP and FDA/EMA manufacturing standards.

Measurable Outcomes

Zai Lab’s regulatory strategy produced measurable results over the 2019–2025 period:

• 7 innovative drug approvals from the NMPA across oncology, autoimmune diseases, and infectious diseases
• Average China-US approval gap reduced from 3.5 years (pre-2017) to 6–12 months by 2023
• 3 Breakthrough Therapy Designations from the CDE, all converting to commercial approvals
• 4 products listed on the NRDL within 2 years of launch, achieving broad patient access
• Regulatory review times averaging 10–14 months for priority-reviewed applications, compared to the pre-reform average of 3–5 years

Key Lessons for Foreign and China Biotech Companies

1. Invest in regulatory affairs early. Zai built an experienced in-house regulatory team before its first NDA filing. Late-stage regulatory hires are rarely effective
2. Embrace simultaneous global development. The days of sequential China entry (US first, China later) are over. Simultaneous IND filing is now the standard for innovative drugs
3. Build China-specific clinical data strategically. While the NMPA accepts foreign data, a well-designed bridging study or integrated China site in a global trial significantly de-risks approval
4. Plan for NRDL pricing from the start. Develop HEOR dossiers and China-specific pricing models during Phase II development, not after approval
5. Maintain regulatory flexibility. The CDE’s expectations evolve rapidly. Companies successful in 2019–2022 cannot assume the same standards will apply in 2025–2026
6. Develop local manufacturing capability. NMPA increasingly favors locally manufactured products, particularly for the NRDL listing process
7. Engage CDE through the entire lifecycle. Communication meetings during clinical development are as important as the formal NDA filing

Key Takeaway

Related Resources

• NMPA Announcement No. 102 of 2017: Priority review mechanism for innovative drugs
• NMPA Breakthrough Therapy Designation Procedures (2020): Application and review process
• NMPA Administrative Measures for Drug Registration (2020 revision): Comprehensive regulatory framework for drug registration
• ICH E6 (R2): Good Clinical Practice standards for integrated global trials